Skip to content

Acupuncture for treatment of joint pain secondary to aromatase inhibitor therapy in women with early breast cancer

Feasibility of use of acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611000149965
Enrollment
30
Registered
2011-02-08
Start date
2009-07-20
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Breast cancer is most common cancer in women. Aproximately 75% of patients diagosed will have hormone receptor positive breast cancer. Tamoxifen has long been considered the gold standard for adjuvant therapy for postmenopausal women with endocrine sensitive early breast cancer. Aromatase inhibitors (AIs) are commonly used and are in fact superior in improving disease free survival. As a result, it is expected that in coming years the use of AIs in the current setting will increase dramatically. However, trials of AIs for breast cancer treatment have indicated that more than 40% of women taking AIs experience joint pain and stiffness which doesn't respond to conventional pain medication and may cause discontinuation of AI treatment. Acupuncture is one such alternative technique currentlyused for treating a variety of conditions including musculoskeletal pain. The analgesic mechanism of acupuncture is uncertain but it is speculated that analgesia may be mediated by release of opiod peptides and serotonin.

Interventions

Acupuncture twice weekly for 6 weeks. The sites which will be used are L14, LI11, GB34, ST40, Du20, Shishencong and Baxie on Day 1(First Session) and GB21, ST36, TH5, SP6 and LIV3 on Day 2 (Second Session). In the treatment group the needles will be inserted with bilateral rotation until "de Qi" sensation is elicited. Electrical frequency will then be delivered over 2 to 10 Hz (as tolerated by the participant, 0.5 to 0.7 milliseconds duration pulse width for twenty minutes. Each session will t

Acupuncture twice weekly for 6 weeks. The sites which will be used are L14, LI11, GB34, ST40, Du20, Shishencong and Baxie on Day 1(First Session) and GB21, ST36, TH5, SP6 and LIV3 on Day 2 (Second Session). In the treatment group the needles will be inserted with bilateral rotation until "de Qi" sensation is elicited. Electrical frequency will then be delivered over 2 to 10 Hz (as tolerated by the participant, 0.5 to 0.7 milliseconds duration pulse width for twenty minutes. Each session will take 30-60 minutes.

Sponsors

Royal Prince Alfred Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Early breast cancer patients taking thrid generaion aromatase inhibitor. Women with ongoing pain and/or stiffness in one or more joints which worsened after starting aromatase inhibitor. Baseline worst pain score on BPI-SF of 3 or greater (scale 0-10)

Exclusion criteria

Previous use of acupuncture for Aromatase Inhibitor induced joint paint Severe concomitant illness or metastatic breast cancer Severe coagulopathy or bleeding disorder or dermatological disease within the acupuncture area (including patients on warfarin or low molecular weight heparin). Patients with cardiac pacemakers, defibrilator or any other implanted or topical electrical device. Needle phobia rendering a patient unable to receive acupuncture. Patients with intellectual or mental impairment

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026